Kyverna Therapeutics, Inc. announced that on January 8, 2026, the Board appointed Christi Shaw, a current member of the Board, as the Company's Executive Chairperson of the Board, effective January 12, 2026. In this role, Ms. Shaw will serve as the Chairperson of the Board. Ian Clark, who served as Kyverna?s Board Chairman, will remain as a Director on the Board.
Ms. Shaw brings significant CAR T-cell therapy experience, having served as the Chief Executive Officer of Kite, a Gilead Company. Under Christi?s leadership, Kite became the global leader in CAR T with multiple approved blood cancer indications in over 20 countries. In addition, Ms. Shaw brings deep immunology and neurology experience from her time at Eli Lilly and Company and Novartis Pharmaceutical Corporation.
